The phase III IPATunity130 is evaluating ipatasertib plus paclitaxel as first‐line therapy for PI3KCA/AKT/PTEN‐altered triple‐negative breast cancer or HR‐positive, HER2‐negative breast cancer. Here, ERBB2 is linked to breast cancer.